# US 2006/0105999 A1 · Novel inhibitors of beta-lactamase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0105999 A1
- Document ID: US20060105999A1
- Status: Published application
- Kind: A1
- Application number: 10/535,391
- Filed: 2003-11-19
- Published: 2006-05-18
- Earliest claimed: 2002-11-22
- Assignees: MethylGene Inc.
- Inventors: Jeffrey Besterman; Jubrail Rahil; Arkadii Vaisburg
- Web page: https://patentgrep.com/patent/US20060105999A1

## CPC

- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- A61P 31/04: Antibacterial agents
- C07F 9/2491: {containing the structure P(=X)n-N-N (X = O, S, Se; n = 0, 1)}
- C07F 9/3808: {Acyclic saturated acids which can have further substituents on alkyl}
- C07F 9/4006: {Esters of acyclic acids which can have further substituents on alkyl}
- C07F 9/4084: {Esters with hydroxyaryl compounds}
- C07F 9/425: {Acid or estermonohalides thereof, e.g. RP(=X)(YR)(Hal) (X, Y = O, S; R = H, or hydrocarbon group)}
- C07F 9/4407: {Amides of acyclic saturated acids which can have further substituents on alkyl}
- C07F 9/572: Five-membered rings
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/58: Pyridine rings
- C07F 9/60: Quinoline or hydrogenated quinoline ring systems
- C07F 9/6506: having the nitrogen atoms in positions 1 and 3
- C07F 9/6524: having four or more nitrogen atoms as the only ring hetero atoms
- C07F 9/65312: {having the two nitrogen atoms in positions 1 and 2}
- C07F 9/6539: Five-membered rings
- C07F 9/65395: {having the two nitrogen atoms in positions 1 and 2}
- C07F 9/6541: condensed with carbocyclic rings or {carbocyclic} ring systems
- C07F 9/65515: {the oxygen atom being part of a five-membered ring}
- C07F 9/65517: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/655345: {the sulfur atom being part of a five-membered ring}
- C07F 9/655354: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic β-lactamase inhibitors presently available, and which do not require β-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

## Claims

### Claim 1

A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein
R1 is phenyl or thien-2-yl, each optionally substituted;
L is a covalent bond, —CH2O—, —C(O)—, or —C(═N—OCH3)—; and
R5 is -halo or —OR10 wherein R10 is phenyl, pyridinyl, or quinolinyl, each optionally substituted,
provided that when L is —CH2O—, R5 is not —F or p-nitrophenyl.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein the substituents are independently selected from —NO2, —CO2H, and halo.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R1 is unsubstituted.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein R5 is selected from:

### Claim 5 (depends on 1)

The compound according to claim 1 wherein R1—L and R5 are selected from the following combinations:
R1—L—
R5
PNP
PNP
PNP
PNP
and
—OH

### Claim 6 (depends on 1)

The compound according to claim 1 wherein the phosphonate moiety is replaced with a thiophosphonate moiety, provided that when R1—L— is benzyloxy, R5 is not —O—PNP.

### Claim 7

A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein
R1 is
R3 is —H or —CO2R9, wherein R9 is -C1-C3-alkyl;
R6 is —L1—A—(L2—B)s, wherein
L1 is C0-C3-alkyl optionally mono- to per-halogenated;
A is C3-C6-cycloalkyl, aryl, or heteroaryl;
L2 is a covalent bond or (C0-C3-hydrocarbyl-X1-(C0-C3-hydrocarbyl), wherein X1 is —C(O)—, —NH—, —NH—C(O)—, —C(O)—NH—, or heteroaryl;
B is —H, C3-C6-cycloalkyl, aryl, or heteroaryl; and
s is 0 or 1;
wherein when s is 0, (L2—B)s is —H or halo, and A and B are independently optionally substituted with 1-3 moieties independently selected from the group consisting of halo, —NO2, —CO2H, —CN, —C(O)—NH2, —SO2—NH2, or -C0-C3-hydrocarbyl-Y-(C1-C3-hydrocarbyl) wherein Y is a covalent bond, —O—C(O)—, —C(O)—, —O—, —S—, —SO2—, —C(O)—NH—, or —NH—C(O)—; and each alkyl moiety is optionally mono- to per-halogenated.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R3 is H and R1 is

### Claim 9 (depends on 7)

The compound according to claim 7 wherein R3 is —CO2Et and R1 is

### Claim 10 (depends on 7)

The compound according to claim 7 wherein L1 is —O— and A is phenyl or pyridinyl, each optionally substituted, R3 is H and R1 is

### Claim 11 (depends on 10)

The compound according to claim 10 wherein A is pyridin-3-yl.

### Claim 12 (depends on 11)

The compound according to claim 11 wherein s is 0.

### Claim 13 (depends on 11)

The compound according to claim 11 wherein s is 1 and L2 is —C(O)—, —C(O)NH—, —NH—, 1,2,4-oxadiazolyl, or 1,3,4-oxadiazolyl and B is phenyl, pyridinyl, cyclopropyl, or thienyl, wherein B is optionally substituted.

### Claim 14 (depends on 13)

The compound according to claim 13 wherein the substituents on the A and B rings are independently selected from —F, —Cl, —Br, —CO2H, —C(O)O—CH3, —CF3, —OCH3, —OCF3, —CH3, —CN, —C(O)NH2, —S—CF3, —SO2CH3, —NO2, —CF3CF3, —SO2CF3, —SO2CF3CF3, and —SO2NH2.

### Claim 15 (depends on 8)

The compound according to claim 8 wherein one or both of the following are true:
a. A is selected from phenyl and pyridinyl;
b. B is selected from phenyl, tetraazolyl, cyclopropyl, pyridinyl, and thienyl.

### Claim 16 (depends on 9)

The compound according to to claim 9, wherein R6 is phenyl or p-nitro phenyl.

### Claim 17 (depends on 8)

The compound according to claim 8 selected from those in which —O—R6 is

### Claim 18

A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein
R1 is
optionally substituted with 1-3 moieties independently selected from the group consisting of —F, —Cl, —Br, —CO2H, —C(O)O—CH3, —CF3, —OCH3, —OCF3, -C1-C6 alkyl, —CN, —C(O)NH2, —S—CF3, —SO2CH3, —NO2, —CF3CF3, —SO2CF3, —SO2CF3CF3, and —SO2NH2;
R6 is —L1—A—(L2—B)s, wherein
L1 is C0-C3-alkyl optionally mono- to per-halogenated;
A is C3-C6-Cycloalkyl, aryl, or heteroaryl;
L2 is a covalent bond or (C0-C3-hydrocarbyl)-X1-(C0-C3-hydrocarbyl), wherein X1 is —C(O)—, —NH—, —NH—C(O)—, —C(O)—NH—, or heteroaryl;
B is —H, C3-C6-cycloalkyl, aryl, or heteroaryl; and
s is 0 or 1;
wherein when s is 0, (L2—B)s is —H or halo, and A and B are independently optionally substituted with 1-3 moieties independently selected from the group consisting of halo, —CF3, —NO2, —CO2H, —CN, —C(O)—NH2, —SO2—NH2, or -C0-C3-hydrocarbyl-Y-(C1-C3-hydrocarbyl) wherein Y is a covalent bond, —O—C(O)—, —C(O)—, —O—, —S—, —SO2—, —C(O)—NH—, or —NH—C(O)—; and each alkyl moiety is optionally mono- to per-halogenated.

### Claim 19 (depends on 18)

The compound according to claim 18 wherein R6 is phenyl optionally substituted with 1-3 moieties independently selected from the group consisting of halo, —CF3, —NO2, —CO2H, —CN, —C(O)—NH2, —SO2—NH2, or -C0-C3-hydrocarbyl-Y-(C1-C3-hydrocarbyl), wherein Y is a covalent bond, —O—C(O)—, —C(O)—, —O—, —S—, —SO2—, —C(O)—NH—,or —NH—C(O)—, and each alkyl moiety is optionally mono- to per-halogenated.

### Claim 20 (depends on 19)

The compound according to claim 19 wherein R1 is optionally substituted with 1 or 2 moieties independently selected from the group consisting of F, Cl, Br and C1-C6 alkyl.

### Claim 21 (depends on 20)

The compound according to claim 20 wherein R1 is

### Claim 22 (depends on 19)

The compound according to claim 19 wherein R6 is phenyl optionally substituted with 1 or 2 moieties independently selected from the group consisting of halo, —CF3, and CN.

### Claim 23 (depends on 22)

The compound according to claim 22 wherein the compound is selected from those in which —O—R6 is;

### Claim 24 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 25 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 26 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 27 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 28 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 29 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 30 (depends on 18)

The compound according to claim 18 having the structure:

### Claim 31 (depends on 1)

A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 32 (depends on 1)

A method of inhibiting β-lactamase, the method comprising contacting a cell with a compound according to claim 1.
